LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor

[1]  J. C. Winter,et al.  5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens , 2002, Pharmacology Biochemistry and Behavior.

[2]  S. Sealfon,et al.  Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex , 2003, The Journal of Neuroscience.

[3]  Martin P Paulus,et al.  Effects of Hallucinogens on Locomotor and Investigatory Activity and Patterns: Influence of 5-HT2A and 5-HT2C Receptors , 1998, Neuropsychopharmacology.

[4]  Stuart C. Sealfon,et al.  Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior , 2007, Neuron.

[5]  M. Kupersmith,et al.  Lisuride in Parkinson disease , 1981, Neurology.

[6]  E. Raffaelli,et al.  Lisuride in Cluster Headache , 1983, Headache.

[7]  G. Kennett,et al.  Modulation of 5-HT2A receptor-mediated head-twitch behaviour in the rat by 5-HT2C receptor agonists , 2001, Pharmacology Biochemistry and Behavior.

[8]  D. Jackson,et al.  Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: Effects of antipsychotics and other agents in rats , 1995, Pharmacology Biochemistry and Behavior.

[9]  F. J. White,et al.  The discriminative stimulus properties of LSD: Mechanisms of action , 1978, Neuropharmacology.

[10]  M. Millan,et al.  Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and α1/α2-Adrenoceptor , 2002, Journal of Pharmacology and Experimental Therapeutics.

[11]  M. Geyer,et al.  8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+)WAY 100,135 and localization of site of action , 2005, Psychopharmacology.

[12]  D. E. Nichols,et al.  Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). , 2002, Journal of medicinal chemistry.

[13]  M. Geyer,et al.  Dopaminergic stimulation disrupts sensorimotor gating in the rat , 2004, Psychopharmacology.

[14]  F. J. White,et al.  Lack of specificity of an animal behavior model for hallucinogenic drug action , 1981, Pharmacology Biochemistry and Behavior.

[15]  F. J. White,et al.  Pharmacological characterization of dopamine autoreceptors in the rat ventral tegmental area: microiontophoretic studies. , 1984, The Journal of pharmacology and experimental therapeutics.

[16]  C. Marsden,et al.  LISURIDE IN PARKINSON'S DISEASE , 1979, The Lancet.

[17]  F. J. White,et al.  Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions. , 1982, Science.

[18]  Sipes Te,et al.  DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT(2A) and not by 5-HT(2C) receptors. , 1995 .

[19]  J. Gillin,et al.  The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: A preliminary report , 1994, Biological Psychiatry.

[20]  R. Horowski,et al.  Effectiveness.of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states , 1980, Journal of endocrinological investigation.

[21]  R. Glennon,et al.  Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis , 1989, Psychopharmacology.

[22]  N. Oshino,et al.  Dual activation by lisuride of central serotonin 5-HT(1A) and dopamine D(2) receptor sites: drug discrimination and receptor binding studies. , 1991, Behavioural pharmacology.

[23]  M. Geyer,et al.  DOI disruption of prepulse inhibition of startle in the rat is mediated by 5‐HT2A and not by 5‐HT2C receptors , 1995, Behavioural pharmacology.

[24]  M. Geyer,et al.  5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice , 2009, Neuropsychopharmacology.

[25]  R. Glennon,et al.  Mechanistic studies on DOM as a discriminative stimulus , 1985, Pharmacology Biochemistry and Behavior.

[26]  M. Geyer,et al.  Patterns of exploration in rats distinguish lisuride from lysergic acid diethylamide , 1985, Pharmacology Biochemistry and Behavior.

[27]  R. Glennon,et al.  Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens , 2004, Psychopharmacology.

[28]  J. Dambrosia,et al.  Lisuride in parkinsonism , 1981, Neurology.

[29]  J. Obeso,et al.  Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients. , 1991, Brain : a journal of neurology.

[30]  R. Mailman,et al.  LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors , 1995, Psychopharmacology.

[31]  E. sanders-Bush,et al.  Role of Gq protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane , 2007, Neuropharmacology.

[32]  R. Schreiber,et al.  (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. , 1995, The Journal of pharmacology and experimental therapeutics.

[33]  L. Towns,et al.  The head-twitch response in the least shrew (Cryptotis parva) is a 5-HT2− and not a 5-HT1C-mediated phenomenon , 1994, Pharmacology Biochemistry and Behavior.

[34]  L. Pieri,et al.  Turning in MFB-lesioned rats and antagonism of neuroleptic-induced catalepsy after lisuride and LSD. , 1978, Life sciences.

[35]  W. Herrmann,et al.  Clinical Effectiveness of Lisuride Hydrogen Maleate: A Double‐Blind Trial Versus Methysergide , 1977, Headache.

[36]  T. Akai,et al.  Terguride, a dopamine D2 partial agonist, as a discriminative stimulus in rats , 1991, Behavioural pharmacology.

[37]  F. J. White,et al.  Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids. , 1982, European journal of pharmacology.

[38]  Franz X Vollenweider,et al.  The Effects of the Preferential 5-HT2A Agonist Psilocybin on Prepulse Inhibition of Startle in Healthy Human Volunteers Depend on Interstimulus Interval , 2007, Neuropsychopharmacology.

[39]  B. Largent,et al.  High‐Affinity Agonist Binding Correlates with Efficacy (Intrinsic Activity) at the Human Serotonin 5‐HT2A and 5‐HT2C Receptors: Evidence Favoring the Ternary Complex and Two‐State Models of Agonist Action , 1999, Journal of neurochemistry.

[40]  E. sanders-Bush.  Neurochemical evidence that hallucinogenic drugs are 5-HT1c receptor agonists: what next? , 1994, NIDA research monograph.

[41]  R. Horowski,et al.  Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans. , 1978, The Journal of clinical endocrinology and metabolism.

[42]  J. Liebman,et al.  Antagonism of l-5-hydroxytryptophan-induced head twitching in rats by lisuride: A mixed 5-hydroxytryptamine agonist-antagonist? , 1985, Neuroscience Letters.

[43]  R. Glennon,et al.  Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors , 1998, Psychopharmacology.

[44]  T. Kenakin,et al.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.

[45]  J. Leysen,et al.  Use of 5-HT Receptor Agonists and Antagonists for the Characterization of Their Respective Receptor Sites , 1989 .

[46]  R. Glennon.  Discriminative stimulus properties of hallucinogens and related designer drugs. , 1991, NIDA research monograph.

[47]  Alan A. Boulton,et al.  Drugs as tools in neurotransmitter research , 1989 .

[48]  V. Watts,et al.  Serotonin 5-Hydroxytryptamine2A Receptor-Coupled Phospholipase C and Phospholipase A2 Signaling Pathways Have Different Receptor Reserves , 2003, Journal of Pharmacology and Experimental Therapeutics.

[49]  R. Glennon.  Do classical hallucinogens act as 5-HT2 agonists or antagonists? , 1990, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[50]  M. Smolka,et al.  Lisuride, a dopamine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[51]  F. J. White,et al.  Comparison of the effects of LSD and lisuride on A10 dopamine neurons in the rat , 1983, Neuropharmacology.

[52]  M. Piercey,et al.  Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. , 1996, European journal of pharmacology.

[53]  R. Kohnen,et al.  Lisuride treatment of Restless Legs Syndrome: first studies with monotherapy in de novo patients and in combination with levodopa in advanced disease , 2005, Journal of Neural Transmission.

[54]  Franz X Vollenweider,et al.  Serotonin research: contributions to understanding psychoses. , 2008, Trends in pharmacological sciences.

[55]  R. Glennon,et al.  Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. , 1984, Life sciences.

[56]  J. C. Winter,et al.  The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs I: Antagonist correlation analysis , 1995, Psychopharmacology.

[57]  Rex Y. Wang,et al.  LSD and DOB: interaction with 5‐HT2A receptors to inhibit NMDA receptor‐mediated transmission in the rat prefrontal cortex , 1999, The European journal of neuroscience.

[58]  A. Grottick,et al.  Effect of LSD on Prepulse Inhibition and Spontaneous Behavior in the Rat: A Pharmacological Analysis and Comparison between Two Rat Strains , 2001, Neuropsychopharmacology.

[59]  B. Pitt.  Psychopharmacology , 1968, Mental Health.

[60]  B. Jacobs,et al.  Behavioral effects of LSD in the cat: Proposal of an animal behavior model for studying the actions of hallucinogenic drugs , 1977, Brain Research.

[61]  D. E. Nichols,et al.  Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats , 2002, Psychopharmacology.

[62]  M. Millan,et al.  Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes , 2002, Journal of Pharmacology and Experimental Therapeutics.

[63]  R. Schreiber,et al.  Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. , 1994, European journal of pharmacology.

[64]  Andreas Bäbler,et al.  Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.

[65]  K. Cunningham,et al.  Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. , 2006, Current topics in medicinal chemistry.

[66]  W. Herrmann,et al.  Migraine Prophylaxis with Lisuride Hydrogen Maleate‐A Double Blind Study of Lisuride Versus Placebo , 1978, Headache.

[67]  D. E. Nichols,et al.  Serotonin receptors. , 2008, Chemical reviews.

[68]  R. Edelberg,et al.  Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum. , 1958, A.M.A. archives of neurology and psychiatry.

[69]  B. Roth,et al.  Agonist high and low affinity state ratios predict drug intrinsic activity and a revised Ternary complex mechanism at serotonin 5‐HT2A and 5‐HT2C receptors , 2000, Synapse.

[70]  M. Millan,et al.  Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes , 2002, Journal of Pharmacology and Experimental Therapeutics.

[71]  G. Aghajanian,et al.  Hallucinogens potentiate responses to serotonin and norepinephrine in the facial motor nucleus. , 1980, Life sciences.

[72]  Glennon Ra.  Discriminative stimulus properties of hallucinogens and related designer drugs. , 1991 .

[73]  M. Breeding,et al.  (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist. , 1991, The Journal of pharmacology and experimental therapeutics.

[74]  M. Geyer,et al.  Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors , 2008, Psychopharmacology.

[75]  B. Jacobs,et al.  Activity of a non-hallucinogenic ergoline derivative, lisuride, in an animal behavior model for hallucinogens , 1981, Psychopharmacology.

[76]  G. Kennett,et al.  Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists. , 2001, Pharmacology, biochemistry, and behavior.

[77]  M. Vance,et al.  Drugs Five Years Later: Bromocriptine , 1984 .

[78]  M. Geyer,et al.  Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats , 1994, Neuropharmacology.

[79]  J. C. Winter,et al.  Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives , 1995, Psychopharmacology.

[80]  D. Cussac,et al.  Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. , 2008, European journal of pharmacology.

[81]  Bromocriptine and lisuride in Parkinson disease , 1983, Annals of neurology.

[82]  D. Marona-Lewicka,et al.  Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI , 2009, Psychopharmacology.